Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced that Jeffs' Brands Ltd., a data-driven e-commerce company operating on the Amazon Marketplace, announced on August 30, 2022, the closing of its initial public offering, and the simultaneous closing of a portion of the underwriter’s over-allotment option, for aggregate gross proceeds of approximately $15.5 million before deducting underwriting discounts and other estimated offering expenses. As a result of the closing of the IPO, Medigus now owns 35.27% of Jeffs' Brands. Jeffs' Brands issued 3,717,473 ordinary shares and 3,717,473 warrants, each to purchase one ordinary share with an initial exercise price of $4.04 per share, at a combined initial public offering price of $4.16 per ordinary share and warrant.

American Resources Corporation (NASDAQ:AREC), a next generation and socially responsible supplier of rare earth and critical elements, carbon and advanced carbon materials to the new infrastructure and electrification marketplace, today announced that its Board of Directors has authorized a stock repurchase program for up to $10,000,000 of its shares of common stock outstanding. The share repurchase authorization will be used at management's discretion and will expire on September 15, 2023, unless further extended by the Board of Directors. The Share Repurchase Program may also be suspended, modified, or discontinued at any time and does not obligate the Company to acquire any amount of Class A common stock.

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE), a global leader in guideline driven genomics-based tests in health, wellness and serious disease, reported excellent commercial progress in the USA strategic operations with the following updates:

• Active engagement with 11 US payer groups with an initial target list of 30 with coverage in tens of millions of lives
• Engagement with 19 US Concierge Medicine Practices with large volume pricing discussions
• Commercial evaluations underway at 10 US medical/family practices
• Re-engagement with 1,600 previous geneType US customers
• Dr Erika Spaeth, a key presenter at the Precision Medicine Leaders Summit in Boston
• Online ordering of geneType Multi-Risk Test with Telehealth support established
• Melbourne laboratory receives US CLIA certification as a “High Complexity Laboratory”
• African American ethnicity validation and research collaboration with Washington State University well underway
• Establishment of a new US operations team dedicated to EasyDNA product sales

QYOU Media Inc., (TSXV: QYOU) ( OTCQB: QYOUF) a company operating in India and the United States producing and distributing content created by social media stars and digital content creators, reported final financial results for the quarter ended June 30, 2022. Highlights include as follows:

• Record Breaking Quarterly and YOY Revenue Growth: For the three months ended June 30, 2022 revenue was $6,883,363 representing a year over year increase of 163% and the highest revenue mark in company history.
• Improved Adjusted EBITDA*: For the three months ended June 30, 2022 compared to the same period prior year, adjusted EBITDA loss was $1,348,082 representing an EBITDA improvement of $666,223 or 33% driven by the revenue growth offset by higher operating expenses related to the growth of the business across all operating business units.
• Net Loss: Net loss for the quarter is $3,297,014, an increase of 7% or $210,362 driven by revenue growth across all business units offset by the launch of new channels and programming.
• Cash Balance: The Company concluded the three months ended June 30, 2022 with cash of $4,181,414 (compared to March 31, 2022 cash of $5,082,637).